CANN GROUP LIMITED (CAN)
Latest AI Signal: SELL
Status: EXPIRED
Days Old: 16
Confidence: 75.00%
Date: 05-05-2026
Price: $0.005
Last Price: $0.005
Post-Signal Low Price: $0.005
Latest CANN GROUP LIMITED(CAN) News
26 Feb 2023, 11:09 AM
Cann Group (ASX:CAN) First Half 2023 Results
Key Financial Results
Net loss: AU$18.8m (loss widened by 128% from 1H 2022). AU$0.053 loss per share (further deteriorated from AU$0.028 loss in 1H 2022). earnings-and-revenue-history
All figures shown in the chart above are for the trailing 12 month
10 Oct 2022, 02:12 PM
This week we saw the Cann Group Limited (ASX:CAN) share price climb by 16%. But that doesn't change the fact that the returns over the last three years have been stomach churning. In that time the share price has melted like a snowball in the desert, down 79%. So it sure is nice to see a bit of an i
03 May 2022, 12:30 PM
Cann Group Limited (ASX:CAN) shareholders will doubtless be very grateful to see the share price up 35% in the last month. But that is meagre solace in the face of the shocking decline over three years. Indeed, the share price is down a whopping 84% in the last three years. So we're relieved for lon
21 Nov 2021, 09:44 AM
As every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses more than once in a while. So take a moment to sympathize with the long term shareholders of Cann Group Limited (ASX:CAN), who have seen the share price tank a massive 88% over a thre
08 Sep 2021, 01:58 AM
BioHarvest Sciences Inc., Icanic Brands Co Inc. & Cann Group Ltd. Among Top Cannabis Gainers For The Week. TerrAscend Corp & Columbia Care Inc Made the Headlines with Positive News. Key Developments to Note in the Proceedings of the Federal Legalization of Marijuana
With State cannabis legalization
Sell Confidence High
AI Confidence - 75.00 % model confidence
Business Overview
Cann Group Limited is an Australian-based company engaged in the cultivation, production, and distribution of medicinal cannabis products. It operates primarily in the emerging medical cannabis market, targeting both domestic and international markets, but faces intense competition and regulatory challenges which limit its market position.
Financial Analysis
| Cash Flow | Weak |
| Debt | Moderate |
| Profitability | Weak |
| Revenue Trend | Downtrend |
Technical Analysis
| Trend | Bearish |
| Momentum | Weak |
| RSI Signal | Oversold |
| Support Level | $ 0.0045 |
| Resistance Level | $ 0.0065 |
Valuation
Valuation - Undervalued
The stock price appears depressed relative to its asset base and growth potential, but valuation is tempered by operational losses and market uncertainty.
Catalysts
• Potential regulatory approvals or expansions into new markets could drive growth.
• Strategic partnerships or capital raises may improve financial stability.
Recommendation
Action - Sell
Timeframe -
Given the weak financials, bearish technicals, and ongoing regulatory risks, the stock presents limited upside in the near term. Investors should avoid exposure until clearer signs of operational improvement emerge.